A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media

A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media


Lead Sponsor: Abbott

Source Abbott
Brief Summary

To compare the safety and efficacy of cefdinir oral suspension, 7 mg/kg every 12 hours for 5 days, to azithromycin oral suspension 10 mg/kg/day (Day 1) then 5 mg/kg/day (Days 2-5) for a total of 5 days, in children between 6 months and 6 years of age, with AOM.

Overall Status Completed
Start Date 2003-11-01
Primary Completion Date 2004-01-01
Phase Phase 4
Study Type Interventional
Primary Outcome
Measure Time Frame
Clinical cure rate at Evaluation 2 9 days
Secondary Outcome
Measure Time Frame
Sustained clinical cure rate at Evaluation 4 25 days
Enrollment 357

Intervention Type: Drug

Intervention Name: cefdinir (Omnicef)

Description: oral suspension, 7 mg/kg every 12 hours for 5 days

Arm Group Label: 1

Intervention Type: Drug

Intervention Name: azithromycin

Description: oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.

Arm Group Label: 2



Inclusion Criteria: - Clinical diagnosis, documented by medical history and physical examination, is AOM I 1 week. - Clinical symptoms include >=1 of the following: Otalgia (earache or pain), this may be expressed as ear pulling or nabbing; Ear fullness; Decreased hearing, this may be based on reports from parents or legally authorized representatives; Discharge from the external auditory canal (following acute perforation of the tympanic membrane). - At least two (2) of the following signs are present in at least one ear: Full or bulging or perforated tympanic membrane, which may be erythematous (note - since hyperemia may be present in a febrile or crying child, a red tympanic membrane alone is insufficient for the diagnosis of AOM); Loss of tympanic membrane landmarks (opacity of the tympanic membrane); Abnormal tympanic membrane mobility on biphasic pneumatic otoscopy, due to the presence of pus or fluid behind the tympanic membrane and edema of the tympanic membrane. Have evidence of middle ear fluid demonstrated by acoustic reflect tympanometry (ear check) showing values of 3, 4 or 5. - Generally in good health based on medical history, vital signs, physical exam, and historical laboratory results. - Subject must be a suitable candidate for oral antibiotic therapy. Exclusion Criteria: - Previous enrollment in this study. - Enrollment in any other investigational study using unapproved products or unapproved doses; in the previous four weeks prior to study start. - Hypersensitivity reactions to cefdinir, other cephalosporins, azithromycin, other macrolide and azalide antibiotics, and/or sensitivity to multiple allergens. - Presence of tympanostorny tubes or otitis externa at Evaluation 1. - Systemic treatment with any anti-infective agent within 14 days prior to Evaluation 1 or during the study. - Treatment with a long-acting injectable antimicrobial agent (e.g., penicillin G benzathine) within 4 weeks prior to study drug administration. - Concomitant infection that requires additional antimicrobial therapy. - Evidence of chronic, suppurative otitis media. - Evidence of perforation of the tympanic membrane > 24 hours. - Evidence of a physiologic, anatomic, or immunologic defect, which would interfere with resolution of this episode of acute otitis media. - Immunocompromised subject (e.g., neutropenic subjects). - Presence of a disease, complicating factor (e.g., mastoiditis), or structural abnormality that would preclude evaluation of the subject's therapeutic response. - Any expectation that treatment with probenecid will be expected during the study drug administration period. - Known significant renal or hepatic impairment.



Minimum Age:

6 Months

Maximum Age:

6 Years

Healthy Volunteers:


| Columbiana, Alabama, 35051, United States
| Montgomery, Alabama, 36116, United States
| Ozark, Alabama, 36360, United States
| Fresno, California, 93710, United States
| Fresno, California, 93720, United States
| Marietta, Georgia, 30062, United States
| Stone Mountain, Georgia, 30087, United States
| Dubuque, Iowa, 52002, United States
| Bardstown, Kentucky, 40004, United States
| Louisville, Kentucky, 40207, United States
| Owensboro, Kentucky, 42303, United States
| Cadillac, Michigan, 49601, United States
| Kalamazoo, Michigan, 49008, United States
| Portage, Michigan, 49024, United States
| Richland, Michigan, 49083, United States
| Omaha, Nebraska, 68178, United States
| Columbus, Ohio, 43205, United States
| Huber Heights, Ohio, 45424, United States
| Pittsburgh, Pennsylvania, 15241, United States
| Reading, Pennsylvania, 19606, United States
| Sellersville, Pennsylvania, 18960, United States
| Charleston, South Carolina, 29425, United States
| Kingsport, Tennessee, 37664, United States
| Lake Jackson, Texas, 77566, United States
| Salt Lake City, Utah, 84109, United States
| Salt Lake City, Utah, 84121, United States
| West Jordan, Utah, 84008, United States
| West Jordan, Utah, 84084, United States
| Vienna, Virginia, 22180, United States
| Monroe, Wisconsin, 53566, United States
Location Countries

United States

Verification Date


Responsible Party

Name Title: Angela M Nilius

Organization: Abbott

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: 1

Type: Active Comparator

Label: 2

Type: Active Comparator

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Single (Investigator)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News